Industry › Clinical Trials

Press Releases

Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China

Jul 25, 2025 10:52 HKT/SGT

冠科生物圣地亚哥实验室获 CLIA 认证增强临床试验支持能力

Jul 23, 2025 09:00 HKT/SGT

冠科生物聖地牙哥實驗室獲 CLIA 認證增強臨床試驗支援能力

Jul 23, 2025 09:00 HKT/SGT

Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support

Jul 23, 2025 09:00 HKT/SGT

CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets

Jul 22, 2025 13:00 HKT/SGT

康哲药业携手新交所共话新兴市场产业国际化与医药出海新范式探索

Jul 18, 2025 13:00 HKT/SGT

耀啟新程！康哲藥業今日於新加坡交易所主板實現二次上市

Jul 15, 2025 17:05 HKT/SGT

耀启新程！康哲药业今日于新加坡交易所主板实现二次上市

Jul 15, 2025 16:53 HKT/SGT

Silo Pharma Enters Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025 21:27 HKT/SGT

康哲藥業建議於新加坡交易所第二上市

Jun 25, 2025 18:13 HKT/SGT

康哲药业建议于新加坡交易所第二上市

Jun 25, 2025 17:24 HKT/SGT

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis

Jun 23, 2025 12:05 HKT/SGT

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

Jun 20, 2025 18:06 HKT/SGT

NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment

Jun 18, 2025 12:40 HKT/SGT

Southeast Asian stem cell leader Medeze launches voluntary conditional cash partial offer for 10% stake in SGX-listed Cordlife Group Limited

May 14, 2025 15:00 HKT/SGT

HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025

Apr 24, 2025 18:43 HKT/SGT

君圣泰医药三项创新研究成果即将亮相2025欧肝会(EASL)

Apr 24, 2025 18:35 HKT/SGT

熊去氧膽小檗堿（HTD1801）一藥多效即將進入商業化新紀元

Apr 15, 2025 08:10 HKT/SGT

熊去氧胆小檗碱（HTD1801）一药多效即将进入商业化新纪元

Apr 15, 2025 08:10 HKT/SGT

Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA

Apr 15, 2025 08:00 HKT/SGT